Literature DB >> 12851027

From zero to one hundred million in six months: the treatment of azoospermia in congenital adrenal hyperplasia.

J D M Nicopoullos1, J W A Ramsay, J Cassar.   

Abstract

In the majority of the 25% of couples in which a male factor is responsible for their infertility, no identifiable pathology is found. It is unusual to be faced with an etiology that is readily amenable to successful treatment without the eventual dependence on assisted reproductive techniques for pregnancy. The diagnosis of congenital adrenal hyperplasia has variable implications on fertility. A case is presented of azoospermia in a man diagnosed with classical non-salt-losing congenital adrenal hyperplasia. Within 9 months of treatment with dexamethasone, his sperm count had risen to above 100 million per milliliter, enough to overcome very poor morphology and a naturally conceived pregnancy ensued. The pregnancy is ongoing. Although an increase in sperm count has been shown in such cases, the degree of improvement in semen parameters is unique, especially in an azoospermic patient.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12851027     DOI: 10.1080/01485010390204940

Source DB:  PubMed          Journal:  Arch Androl        ISSN: 0148-5016


  3 in total

1.  Late diagnosis of classic congenital adrenal hyperplasia: long-term consequences during adulthood.

Authors:  Mariana Aveiro-Lavrador; Adriana De Sousa Lages; Luísa Barros; Isabel Paiva
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2021-05-01

2.  Sperm retrieval and concomitant tumor resection in azoospermic men with congenital adrenal hyperplasia and bilateral testicular adrenal rest tumors: a case report.

Authors:  Parviz K Kavoussi; Roxanne B Summers-Colquitt; Kate C Odenwald; Megan Kressin; Keikhosrow M Kavoussi; Thomas B Pool; Shahryar K Kavoussi
Journal:  J Assist Reprod Genet       Date:  2016-02-09       Impact factor: 3.412

Review 3.  Medical management of non-obstructive azoospermia.

Authors:  Rajeev Kumar
Journal:  Clinics (Sao Paulo)       Date:  2013       Impact factor: 2.365

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.